Altshuler Shaham
SAGE icon

Altshuler Shaham’s Sage Therapeutics SAGE Stock Holding History

Altshuler Shaham’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,403
Closed -$105K – 721
2021
Q1 		$105K Buy
+1,403
New +$115K ﹤0.01% 215
2020
Q2 		– Sell
-200
Closed -$6K – 535
2020
Q1 		$6K Sell
200
-1,163
-85% -$67.3K ﹤0.01% 339
2019
Q4 		$98K Buy
1,363
+200
+17% +$24.6K ﹤0.01% 179
2019
Q3 		$166K Buy
1,163
+49
+4% +$8.2K 0.01% 170
2019
Q2 		$204K Sell
1,114
-5,673
-84% -$968K 0.01% 115
2019
Q1 		$1.08M Buy
6,787
+5,268
+347% +$763K 0.05% 85
2018
Q4 		$146K Sell
1,519
-31
-2% -$3.55K 0.01% 113
2018
Q3 		$219K Hold
1,550
– – 0.01% 106
2018
Q2 		$243K Hold
1,550
– – 0.02% 101
2018
Q1 		$250K Buy
+1,550
New +$263K 0.03% 106

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Altshuler Shaham's SAGE Position: Q2 2021 in Review

Altshuler Shaham sold out of Sage Therapeutics (SAGE) in Q2 2021, closing a stake of 1,403 shares — an estimated $105K sold.

Altshuler Shaham first reported a position in SAGE in Q1 2018 and held it in 10 quarters. The position peaked at $1.08M in Q1 2019. 257 funds tracked by Wall St. Rank hold SAGE as of Q2 2021.

  • Altshuler Shaham reported no remaining Sage Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Altshuler Shaham sold 1,403 Sage Therapeutics shares in Q2 2021, an estimated $105K.
  • Altshuler Shaham first reported a position in Sage Therapeutics in Q1 2018 and held it in 10 quarters.
  • Altshuler Shaham's Sage Therapeutics position peaked at $1.08M in Q1 2019.
  • 257 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2021.

Based on Altshuler Shaham's 13F filing for Q2 2021, filed 16 Aug 2021.